window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 20, 2026

  • News
  • About Us
Contact Us

CNS disorders

  • Artificial Intelligence,Clinical studies,Digital Health,Medical devices,Neurosciences

    Neuraxpharm and mjn-neuro plan launch of digital solution for early detection of epileptic seizures

    Neuraxpharm and mjn-neuro are preparing to launch a digital health [...]

    December 3, 2025
  • Central Nervous System,Chronic diseases,Drug Delivery & Formulation,European biotech,Pharmaceuticals and therapeutics

    Neuraxpharm launches next-generation oral fumarate Riulvy for multiple sclerosis in Germany

    Neuraxpharm Group has launched Riulvy (tegomil fumarate) in Germany, marking [...]

    October 3, 2025
  • Drug Development,Neurosciences,Rare Diseases,Regulatory Affairs

    SOM Biotech secures EMA orphan designation opinion for Huntington’s drug SOM3355

    Barcelona-based biotech advances Huntington’s programme as EMA backs orphan designation, [...]

    September 15, 2025
  • Central Nervous System,Clinical Trials,Digital Health,Pharmaceuticals and therapeutics

    Investigational schizophrenia digital therapeutic meets key goal in late-stage study

    An investigational prescription digital therapeutic (PDT) designed to treat negative [...]

    August 14, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Development,Market Access & Commercialization,Oncology,Patient Centricity,Regulatory Affairs,Research & Development

    Neuraxpharm expands global reach with launch of Australian affiliate

    Neuraxpharm Group, a leading European specialty pharmaceutical company focused on [...]

    July 22, 2025
  • Drug Development,Precision medicine

    Elkedonia raises EUR 11.25 million to develop new treatment for depression and other neuropsychiatric disorders

    New approach targets Elk1 to restore neuroplasticity without sedation or [...]

    June 12, 2025
  • Clinical Trials,Drug Development

    FTD trial milestone reached as Vesper Bio enrols first asymptomatic GRN carriers

    Vesper Bio has reached a key enrolment milestone in its [...]

    May 12, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cereno Scientific publishes first peer-reviewed data on HDAC inhibitor CS014 showing antithrombotic effects without bleeding risk
    Categories: Biotech, Clinical Development, Drug Development, European biotech, Hematology, Research & Development, Respiratory
  • SPT Labtech adds automated Twist Bioscience NGS library preparation workflows to firefly platform
    Categories: Data Management, Genomics and sequencing, Research & Development, Technology and platforms
  • Almirall to launch phase 3 LumiNE study of lebrikizumab in nummular eczema
    Categories: Clinical Trials, Dermatology, Drug Development, European biotech, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top